Americans spend billions of dollars each year on over-the-counter and pharmaceutical drugs. The manufacturers of these drugs actively market them to both physicians and their patients as treatment for everything from pain relief to weight loss. Unfortunately, the competition among manufacturers for the marketplace for these drugs can often lead to manufacturing and marketing decisions which do not have the safety of consumers at heart. Sometimes, drug manufacturers at best overlook, and at worst conceal, known or knowable hazards inherent in the drugs they market with devastating effects on an unwary public.
Attorneys at Richardson, Patrick, Westbrook & Brickman have participated in the litigation of numerous cases involving dangerous prescription drugs, including Baycol (link to hist and success of Baycol), Stadol, Rezulin (link to current lawsuit of Rezulin) and Fen-Phen (link to hist and success Fen-Phen). Our attorneys have been at the forefront of litigating these complex cases on both an individual basis and in consolidated multi-district litigations and class actions.
Currently, RPWB's pharmaceutical litigation team is active in litigation involving phenylpropanlomine (PPA) — an ingredient in over-the-counter weight loss drugs and decongestants until the year 2000; Zyprexa — an anti-psychotic linked to an increased risk for diabetes and related metabolic disorders; and cox-2 inhibitors such as Vioxx, Celebrex and Bextra — pain relievers linked to an increased risk of heart attack and stroke.
RPWB attorneys, in conjunction with their Canadian co-counsel, recently achieved a significant class action settlement for Canadian citizens against Bristol-Myers Squibb Canada. Those cases, brought in the provinces of Ontario and Quebec, will provide compensation for Canadians who became addicted to the Stadol NS migraine nasal spray.
Please
contact us with any questions or if you'd like to explore your legal rights.
